Regeneron Pharmaceuticals Inc almost doubled its 2012 sales estimate for recently authorized Eylea, the second time it has done so this year, as the eye drug quickly gained share from competing products.
Regeneron currently anticipates sales of $500 million to $550 million from the drug this year, higher from the $250 million to $300 million range it predicted in February.
Cowen and Co analyst Phil Nadeau commented in a note to clients that investors were predicting a rise in 2012 Eylea outlook to the $400 million range.
Its competitors include Amgen, Inc. (NASDAQ:AMGN) that surged 1.03% to $70.91 with the total traded volume of 1.99 million shares and Novartis AG (ADR) (NYSE:NVS) that moved up 0.57% to $55.16 with the total traded volume of 552,776.00 shares.
Other Healthcare stocks with bullish trend include Watson Pharmaceuticals, Inc. (NYSE:WPI) up 5.73% to $73.68, Amarin Corporation plc (ADR) (NASDAQ:AMRN) up 17.43% to $11.72 and Incyte Corporation (NASDAQ:INCY) up 11.03% to $21.54, whereas with bearish trend include Aetna Inc. (NYSE:AET) down -10.72% to $44.07, Tenet Healthcare Corporation (NYSE:THC) down -4.38% to $5.24 and AstraZeneca plc (ADR) (NYSE:AZN) down -5.55% to $43.36.
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) after opening at $143.06 hit high price of $145.04 and then trading at $138.96 by surging +9.32% and on current session volume of 2.12 million shares is surprisingly higher than its average volume of 772,398.00 shares.
The stock price volatility was 2.98% for a week and 3.07% for a month as well as price volatility’s Average True Range for 14 days was 3.79and its beta remained 1.12.
The liquidity measure in recent quarter results of the company was recorded 4.40 as current ratio and on the other side the debt to equity ratio was 0.90 and long-term debt to equity ratio also remained 0.89. The Company had total cash at hand $526.94 million and a book value per share as $5.28 in the most recent quarter.
REGN generated revenue of 445.82 million in the following twelve months and earned -$221.76 million. The Company showed a negative -49.74% in the net profit margin and as well as in its operating margin which remained -46.02%. Company’s annual sales growth for the past five year was 47.69%.
DO NOT TRADE ANY STOCK WITHOUT LEVEL 2 STOCK QUOTES! QuoteDaddy.com delivers it's user with the most in-depth Level 2 Quotation System available on the Planet! NO Downloads, NO Widgets, NO Plugins required! Stay on TOP of your trades with QuoteDaddy.com! CLICK HERE TO START YOUR FREE 30-DAY TRIAL